Literature DB >> 23772668

RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development.

Russell C DeKelver1, Benjamin Lewin, Stephanie Weng, Ming Yan, Joseph Biggs, Dong-Er Zhang.   

Abstract

The 8;21 translocation is the most common chromosomal aberration occurring in acute myeloid leukemia (AML). This translocation causes expression of the RUNX1-ETO (AML1-ETO) fusion protein, which cooperates with additional mutations in leukemia development. We report here that interferons (IFNs) and IFN-stimulated genes are a group of genes consistently up-regulated by RUNX1-ETO in both human and murine models. RUNX1-ETO-induced up-regulation of IFN-stimulated genes occurs primarily via type I IFN signaling with a requirement for the IFNAR complex. Addition of exogenous IFN in vitro significantly reduces the increase in self-renewal potential induced by both RUNX1-ETO and its leukemogenic splicing isoform RUNX1-ETO9a. Finally, loss of type I IFN signaling via knockout of Ifnar1 significantly accelerates leukemogenesis in a t(8;21) murine model. This demonstrates the role of increased IFN signaling as an important factor inhibiting t(8;21) fusion protein function and leukemia development and supports the use of type I IFNs in the treatment of AML.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23772668      PMCID: PMC3987666          DOI: 10.3109/10428194.2013.815351

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  44 in total

1.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

2.  Virus interference. I. The interferon.

Authors:  A ISAACS; J LINDENMANN
Journal:  Proc R Soc Lond B Biol Sci       Date:  1957-09-12

Review 3.  Mechanisms of type-I- and type-II-interferon-mediated signalling.

Authors:  Leonidas C Platanias
Journal:  Nat Rev Immunol       Date:  2005-05       Impact factor: 53.106

Review 4.  Interferon signalling network in innate defence.

Authors:  Akinori Takaoka; Hideyuki Yanai
Journal:  Cell Microbiol       Date:  2006-06       Impact factor: 3.715

5.  Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity.

Authors:  Yizhou Liu; Wei Chen; Justin Gaudet; Matthew D Cheney; Liya Roudaia; Tomasz Cierpicki; Rachel C Klet; Kari Hartman; Thomas M Laue; Nancy A Speck; John H Bushweller
Journal:  Cancer Cell       Date:  2007-06       Impact factor: 31.743

6.  Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays.

Authors:  S D Der; A Zhou; B R Williams; R H Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

7.  Alpha-interferon as induction and maintenance therapy in hairy cell leukemia: a long-term follow-up analysis.

Authors:  E E Damasio; M Clavio; B Masoudi; A Isaza; M Spriano; E Rossi; S Casciaro; R Cerri; M Risso; S Nati; M Siccardi; M Truini; M Gobbi
Journal:  Eur J Haematol       Date:  2000-01       Impact factor: 2.997

Review 8.  Current treatment of acute myeloid leukemia.

Authors:  Gail J Roboz
Journal:  Curr Opin Oncol       Date:  2012-11       Impact factor: 3.645

9.  Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials. MRC Adult Leukaemia Working Party.

Authors:  S E Langabeer; H Walker; J R Rogers; A K Burnett; K Wheatley; D Swirsky; A H Goldstone; D C Linch
Journal:  Br J Haematol       Date:  1997-12       Impact factor: 6.998

Review 10.  The role of interferon-alpha in the treatment of chronic myeloid leukemia.

Authors:  Lisa A Kujawski; Moshe Talpaz
Journal:  Cytokine Growth Factor Rev       Date:  2007-08-20       Impact factor: 7.638

View more
  3 in total

1.  Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia.

Authors:  Bin Zhao; Sabyasachi Bhattacharya; Qiujing Yu; Serge Y Fuchs
Journal:  Leuk Lymphoma       Date:  2017-05-15

Review 2.  Towards a Better Understanding of Cohesin Mutations in AML.

Authors:  Sergi Cuartero; Andrew J Innes; Matthias Merkenschlager
Journal:  Front Oncol       Date:  2019-09-09       Impact factor: 6.244

Review 3.  AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms.

Authors:  Kai Rejeski; Jesús Duque-Afonso; Michael Lübbert
Journal:  Oncogene       Date:  2021-07-30       Impact factor: 9.867

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.